Genexine's new anticancer drug candidate GX-I7, which had shown potential as a treatment for COVID-19, will launch a new clinical trial for anticancer drugs.

On the 10th, the MFDS approved phase 2 clinical trials of Bevacizumab and Genexine GX-I7 in recurrent glioblastoma. Bevacizumab is the active ingredient of Roche's target anticancer drug Avastin. GX-I7 is a substance that Genexine is developing as a new anticancer drug. In 2017, the company launched phase 1b clinical trials for metastatic and recurrent solid cancer and began developing new anticancer drugs in earnest.

Since then, he has initiated phase 1b combination therapy with cyclophosphamide in solid cancer in 2018, phase 1b/2